HLS Therapeutics (TSE:HLS) Shares Down 0.3% – What’s Next?

Shares of HLS Therapeutics Inc. (TSE:HLS) traded down 0.3% on Friday . The company traded as low as C$3.33 and last traded at C$3.64. 59,500 shares were traded during trading, an increase of 111% from the average session volume of 28,252 shares. The stock had previously closed at C$3.65.

Analysts Set New Price Targets

Separately, Raymond James lifted their price objective on HLS Therapeutics from C$4.00 to C$5.00 in a research note on Friday, November 22nd.

HLS Therapeutics Stock Performance

The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44. The firm has a market capitalization of C$115.72 million, a P/E ratio of -3.60 and a beta of 1.07. The business’s 50 day simple moving average is C$3.55 and its two-hundred day simple moving average is C$3.44.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.